TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

In Phase A, individuals will get unique doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Added individuals will probably be enrolled in the recognized monotherapy dosign program. In Section B, participants will get oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Phase C, participants will